November 22, 2019   ISSUE ALERT Volume 44, Issue 19 Check out the digital edition!   Oral therapy targets Stargardt, dry AMD RBS-008 is a novel oral therapy for Stargardt disease and age-related macular degeneration that was shown to effectively reduce the serum biomarker RBP4. Find out more   Conjunctival melanoma: Unlocking the mysteries of disease The future of conjunctival melanoma research is gaining a better understanding of the biomarkers of the disease. Learn more   LIGHT Trial focuses on lowering IOP, keeping it there Ultra-low-dose radiation therapy is showing promises as a treatment for low-grade lymphoma of the orbit and ocular surface. Learn more   JOB OPPORTUNITIES   VT - University of Vermont